Since it began spreading in the spring and migrated to the US shortly thereafter, monkeypox has yet to explode from an outbreak into a bigger epidemic, let alone a pandemic, and infection rates are already showing signs of plateauing in many areas. Still, the world isn’t out of the woods yet, with large-scale growth of infections still possible. To that end, a small pipeline of drug and vaccine candidates has emerged, many of them repurposed products originally developed for smallpox, despite some hitches in getting programs off the ground.
Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections
Most Products Remain In Preclinical Development
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.
More from Anti-infective
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
• By
Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.
• By
The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.
• By
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus